& Immunology (AAAAI)/Food Allergy Initiative, the Gerber Foundation, the Dorothy and Frank Robins Family, the National Peanut Board, the Howard Gittis Memorial 3rd Year/4th Year Fellowship/Instructor Award (to J.A.B.), and the Wallace Research Foundation (grant no. WRF2010.01). Additional support for the project was provided by the National Center for Research Resources (NCRR, grant no. UL1RR02...

“black-box” warnings for all antipsychotic drugs.2 Antipsychotic agents may be classified in several ways. Commonly, they can be designated as older drugs (often called conventional or “typical” antipsychotics) and newer “atypicals.” The term atypical refers to the perceived lower likelihood of extrapyramidal symptoms, a sequela that had been deemed characteristic of the first generation of ant...

Background: Sugammadex selectively binds steroidal neuromuscular blocking drugs, leading to reversal of neuromuscular blockade. The authors developed a pharmacokinetic-pharmacodynamic model for reversal of neuromuscular blockade by sugammadex, assuming that reversal results from a decrease of free drug in plasma and/or neuromuscular junction. The model was applied for predicting the interaction...

PURPOSE A therapeutic lyophilized melanoma vaccine consisting of two mechanically disrupted allogeneic melanoma cell lines and the immunological adjuvant Detox-PC (Melacine) has demonstrated encouraging activity in metastatic malignant melanoma, often in regimens containing pretreatment with low-dose cyclophosphamide. In addition, IFN-alpha2b (INTRON A; Schering-Plough Corporation, Kenilworth, ...

PURPOSE This is the first study to evaluate the tolerability and activity of liposomal doxorubicin (Caelyx; Schering-Plough Pharmaceuticals) < or =60 mg/km(2) in patients with locally recurrent breast cancer, when administered in conjunction with reirradiation and local hyperthermia treatment. EXPERIMENTAL DESIGN Fifteen female patients, who had undergone a radical mastectomy and conventional...

Inadequate response to tumor necrosis factor (TNF )–blocking therapy in rheumatoid arthritis (RA) may result from the formation of antibodies against these drugs (1). Previous studies have shown that polymorphisms in the promoter region of the gene for interleukin-10 (IL-10), a cytokine with a key role in antibody formation, are associated with the formation of antibodies that inhibit recombina...

The use of granulocyte-macrophage colony-stimulating factor (GM-CSF) administered before or in combination with chemotherapy represents a new strategy in the treatment of acute myeloid leukemia (AML). This cytokine is a known growth promoter of leukemic colony-forming cells',* and can recruit quiescent cells into cycle, possibly increasing their chemosensitivity. However, in vivo GM-CSF priming...

Purpose: A therapeutic lyophilized melanoma vaccine consisting of two mechanically disrupted allogeneic melanoma cell lines and the immunological adjuvant Detox-PC (Melacine) has demonstrated encouraging activity in metastatic malignant melanoma, often in regimens containing pretreatment with low-dose cyclophosphamide. In addition, IFN2b (INTRON A; Schering-Plough Corporation, Kenilworth, NJ) h...

Of the 37,485 americans who lost their lives in 2009 to illicit drug use, prescription pain medications caused more deaths than heroin and cocaine combined. Opiates are misused more than any other class of prescription medications. Opiate dependence affects an estimated 1.9 million Americans. Reckitt Benckiser, a British-based company, brought Suboxone (buprenorphine/naloxone) to market in 2002...

In the last decade, biological agents have revolutionised rheumatology. Tumour necrosis factorα (TNF α ) neutralising antibody constructs as infl iximab and adalimumab are widely used as treatment for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and psoriasis. Infl iximab is a chimeric (mouse-human) monoclonal antibody against TNF α . It has been shown to induce the formati...